Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189832 | 0.72 | TRPA1 (0.38) | — | |
| SCHEMBL5840850 | 0.70 | HTR2C (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL5311927 | 0.70 | TRPA1 (0.39) | — | |
| SCHEMBL3357562 | 0.68 | TRPA1 (0.39) | — | |
| SCHEMBL30516101 | 0.68 | TRPA1 (0.39) | — | |
| SCHEMBL1768593 | 0.67 | MAPK1 (0.42) | — | |
| SCHEMBL2929155 | 0.67 | CYP4F2 (0.38) | HTR2C | |
| SCHEMBL3373171 | 0.65 | SNCA (0.36) | — | |
| SCHEMBL29783216 | 0.63 | HPGD (0.39) | — | |
| SCHEMBL5448098 | 0.63 | ALOX15 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644337-B1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | ORE PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | HTR2A 146/4885HTR2C 88/4885HTR2B 85/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | HTR2A 161/4885HTR2C 111/4885HTR2B 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.